Showing 91-100 of 9661 results for "".
- Dr. Shawn Kwatra Analyzes ADtouch Data on Hand and Foot Atopic Dermatitishttps://practicaldermatology.com/news/dr-shawn-kwatra-analyzes-adtouch-data-on-hand-and-foot-atopic-dermatitis/2488634/New Phase 3b ADtouch data for lebrikizumab-lbkz (Ebglyss; Eli Lilly and Company) may help broaden how dermatologists assess disease burden in patients with atopic dermatitis (AD) affecting high-impact areas, according to study investigator Shawn Kwatra, MD.
- Dr. Alexa Kimball Highlights Early Response, HiSCR75 Findings With Tulisokibart in Hidradenitis Suppurativahttps://practicaldermatology.com/news/dr-alexa-kimball-highlights-early-response-hiscr75-findings-with-tulisokibart-in-hidradenitis-suppurativa/2488609/New Phase 2b data for tulisokibart may provide early clinical evidence supporting tumor necrosis factor-like cytokine 1A (TL1A) as a therapeutic target in hidradenitis suppurativa (HS), according to study investigator Alexa Kimball, MD, MPH.
- Sun Pharma Reports 2-Year Deuruxolitinib Data in Severe Alopecia Areatahttps://practicaldermatology.com/news/sun-pharma-reports-2-year-deuruxolitinib-data-in-severe-alopecia-areata/2488607/Long-term treatment with deuruxolitinib (LEQSELVI, Sun Pharmaceutical Industries Limited) showed sustained scalp hair response through Week 108 among selected responders with severe alopecia areata (AA), according to open-label extension (OLE) data presented at the 2026 European Academy of Dermat
- Delgocitinib Shows Real-World and Adolescent CHE Outcomes: Studyhttps://practicaldermatology.com/news/eadv-2026-delgocitinib-shows-real-world-and-adolescent-che-outcomes/2488596/LEO Pharma presented new delgocitinib cream data at the 35th European Academy of Dermatology and Venereology (EADV) Congress, including interim real-world findings in adults and post hoc phase 3 analyses examining symptoms and quality of life in adolescents with moderate to
- New Tralokinumab Data Focus On High-Burden Atopic Dermatitishttps://practicaldermatology.com/news/new-tralokinumab-data-focus-on-high-burden-atopic-dermatitis/2488608/LEO Pharma presented new analyses of tralokinumab (Adtralza; Adbry [tralokinumab-ldrm]) in adults and adolescents with atopic dermatitis (AD) at the 35th European Academy of Dermatology and Venereology (EADV) Congress in Vienna, including real-world findings from TRACE, pha
- Lebrikizumab Improves Hand and Foot AD in Phase 3b ADtouch Trialhttps://practicaldermatology.com/news/lebrikizumab-improves-hand-and-foot-ad-in-phase-3b-adtouch-trial/2488591/Lebrikizumab-lbkz (Ebglyss; Eli Lilly and Company) improved skin clearance, itch, and pain compared with placebo among adults and adolescents with moderate-to-severe atopic dermatitis (AD) affecting the hands and feet, according to Phase 3b ADtouch results presented at the
- Olumiant Gains FDA Approval for Severe Alopecia Areata in Patients 12 and Olderhttps://practicaldermatology.com/news/olumiant-gains-fda-approval-for-severe-alopecia-areata-in-patients-12-and-older/2488595/The FDA has approved Eli Lilly and Company’s Olumiant (baricitinib) for patients aged 12 years and older with severe alopecia areata (AA), expanding the oral Janus kinase (JAK) inhibitor’s US indication to adolescents, according to an announcement from the manufacturer. The
- Simone Biles Shares Seborrheic Dermatitis, Eczema Journey in New Arcutis Campaignhttps://practicaldermatology.com/news/simone-biles-shares-seborrheic-dermatitis-eczema-journey-in-new-arcutis-campaign/2488580/Arcutis has partnered with World Champion gymnast Simone Biles to launch Skin to Believe In, an awareness campaign focused on seborrheic dermatitis and atopic dermatitis, according to a press release from the company. The campaign centers on Biles’ experience managin
- Galderma EADV Data to Explore Nemolizumab, Acne, and Fragile Skinhttps://practicaldermatology.com/news/galderma-eadv-data-to-explore-nemolizumab-acne-and-fragile-skin/2488562/Galderma announced it will be presenting 19 abstracts, including 2 oral presentations, at the 2026 European Academy of Dermatology and Venereology (EADV) Congress, with research spanning inflammatory skin diseases, sensitive and fragile skin, skin longevity, and acne. <
- Science of Skin Summit: AI in Medicine Requires More Than Knowing Which Model Scores Besthttps://practicaldermatology.com/news/science-of-skin-summit-ai-in-medicine-requires-more-than-knowing-which-model-scores-best/2488531/Artificial intelligence models are evolving so rapidly that clinicians may struggle to determine which tools they can trust, but choosing the model that performs best on a standardized test may not provide the answer. Speaking at the Science of Skin Summit, Roxana Daneshjou, MD, PhD, discu